Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coblopasvir
- Development stage
- Phase 3
- Lead developer
- Kawin Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Coblopasvir is a small molecule antiviral drug developed for the treatment of chronic hepatitis C virus (HCV) infection. It acts as an NS5A inhibitor, specifically targeting the nonstructural protein 5A of HCV to inhibit viral replication and assembly. Coblopasvir is used in combination with sofosbuvir for the treatment of chronic HCV genotypes 1, 2, 3, and 6 in adults who are treatment-naïve or have previously received interferon-based therapy, including those with compensated cirrhosis[7][3][4]. The drug was developed by Beijing Kawin Technology Share-Holding and has been approved in China through a priority review process[7][3].
- Brand names
- 凯力唯Kailiwei
- Other names
- coblopasvir hydrochlorideKW-136 hydrochlorideKW136 hydrochlorideKW 136 hydrochloride
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on coblopasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coblopasvir.